Open AccessOrai1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension
Author(s) -
Bastien Masson,
Hélène Le Ribeuz,
Jessica Sabourin,
Loann Laubry,
Emily Woodhouse,
Richard Foster,
Yann Ruchon,
Mary Dutheil,
Angèle Boët,
Maria-Rosa Ghigna,
Vincent de Montpréville,
Olaf Mercier,
David J Beech,
Jean-Pierre Benitah,
Marc A. Bailey,
Marc Humbert,
David Montani,
Véronique Capuano,
Fabrice Antigny
Publication year - 2022
Publication title -
circulation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.899
H-Index - 336
eISSN - 1524-4571
pISSN - 0009-7330
DOI - 10.1161/circresaha.122.321041
Subject(s) - orai1 , pharmacology , chemistry , nfat , in vivo , hypoxia (environmental) , pulmonary hypertension , contractility , downregulation and upregulation , calcineurin , medicine , microbiology and biotechnology , cancer research , biology , calcium , voltage dependent calcium channel , biochemistry , transplantation , organic chemistry , oxygen , gene
Pulmonary arterial hypertension (PAH) is characterized by progressive distal pulmonary artery (PA) obstruction, leading to right ventricular hypertrophy and failure. Exacerbated intracellular calcium (Ca 2+ ) signaling contributes to abnormalities in PA smooth muscle cells (PASMCs), including aberrant proliferation, apoptosis resistance, exacerbated migration, and arterial contractility. Store-operated Ca 2+ entry is involved in Ca 2+ homeostasis in PASMCs, but its properties in PAH are unclear.